Oncternal Therapeutics to Host Call on Cirmtuzumab and the Current Treatment Landscape for Mantle Cell LymphomaBusiness Wire • 07/27/20
Oncternal Therapeutics Announces $6.2 Million Registered Direct Offering Priced At-the-Market under Nasdaq RulesBusiness Wire • 07/20/20
Oncternal Therapeutics Announces Orphan Drug Designations of Cirmtuzumab ROR1 Antibody for Treatment of Mantle Cell Lymphoma and for Treatment of Chronic Lymphocytic LeukemiaBusiness Wire • 06/30/20
Oncternal Therapeutics Announces Increased Focus of the Cirmtuzumab ROR1 Antibody Program on Mantle Cell LymphomaBusiness Wire • 06/30/20
Oncternal Therapeutics, Inc. (ONCT) CEO Dr. Jim Breitmeyer on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/10/20
Oncternal Therapeutics, Inc. (ONCT) CEO Dr. Jim Breitmeyer on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 03/17/20